Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-8264 for prevention of acute kidney injury and major adverse kidney events after cardiac surgery
NL-OMON60040Phase 2Completed
- Sponsor
- Genentech
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute kidney failure (AKF) comparing GDC-8264 with Placebo (2 arms). Primary endpoints: MAKE90 and Safety. Started Feb 2025; status: completed.
02
Drugs
GDC-8264
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on NL-OMON60040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60040.